Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Alzheimer’s Disease Diagnostic Market Growth in 2025?

The market size for diagnosing Alzheimer’s disease has seen substantial growth lately. It’s projected to increase from $6.56 billion in 2024 to $7.28 billion in 2025, maintaining a compound annual growth rate (CAGR) of 11%. The growth in this historic period is driven by factors such as a surge in Alzheimer’s disease and dementia cases, an increased understanding of the necessity for timely diagnosis for improved management, advancements made in imaging technologies like MRI and PET scans, a rise in investment for research and development into neurodegenerative diseases, as well as government-led initiatives and funding towards Alzheimer’s research and diagnostics.

What Is the Forecast for the Alzheimer’s Disease Diagnostic Market Size Through 2029?

The market size for Alzheimer’s disease diagnosis is predicted to witness substantial expansion in the coming years, reaching $10.91 billion by 2029 with a 10.7% compound annual growth rate (CAGR). The projected surge during this forecast period is associated with the evolution of blood-based biomarkers for non-invasive diagnostics, escalating demand for tailor-made medicine and precision diagnostics, incorporation of AI and machine learning in diagnostic equipment for precocious detection, rising utilization of digital health technology for remote monitoring and diagnosis, and upgrade of health care infrastructure in emerging markets for enhanced accessibility. Key trends expected during this period include the advent of multi-dimensional diagnostic strategies integrating imaging, biomarkers, and cognitive tests; a growing emphasis on point-of-care diagnostic procedures for quicker outcomes; the creation of wearable gadgets for perpetual monitoring of cognitive health; increasing cooperation between biotech firms and research institutions for groundbreaking solutions; and the expansion in direct-to-consumer genetic testing for Alzheimer’s risk evaluation.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

What are the Key Market Players in Alzheimer’s Disease Diagnostic Market and How They’re Evolving?

Major companies operating in the alzheimer’s disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation

What Are the Primary Growth Drivers in the Alzheimer’s Disease Diagnostic Market?

The surge in chronic illnesses is projected to stimulate the development of the market for Alzheimer’s disease diagnostics. Chronic illness, characterized by health conditions that persist or last for more than three months, is being fueled by an increased occurrence of a range of interlinked factors such as lifestyle decisions, environmental impacts, genetic factors, and socioeconomic conditions. Having chronic conditions like cardiovascular problems, diabetes, and high blood pressure heightens the likelihood of developing Alzheimer’s disease (AD) and other forms of dementia. For example, a report by the American Heart Association Inc., a non-profit organization based in the U.S., revealed in January 2022 that the incidence of brain disorders in the U.S. is likely to escalate to 9.3 million by 2060, and presently this number is on the rise in the U.S., with one out of every six people globally affected by a brain disease. Currently, by 2021, it is projected that 1 billion people will be affected by brain disorders globally. Consequently, the rise in chronic illnesses is likely to bolster the expansion of the market for Alzheimer’s disease diagnostics.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp

What Are the Leading Segments in the Global Alzheimer’s Disease Diagnostic Industry?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

What Are the Key Market Trends in the Alzheimer’s Disease Diagnostic Industry?

Major corporations in the diagnostic market for Alzheimer’s disease are directing their efforts towards enhancing blood-based biomarker tests, which could streamline the diagnostic procedure for Alzheimer’s disease. This progression would lessen the dependence on more invasive procedures and augment the availability of prompt treatment for patients. To illustrate, Quanterix, a biotechnology research firm from the US, launched the LucentAD p-Tau 217 test in October 2023. This test is a biomarker for Alzheimer’s pathology with clinical sensitivity and specificity in blood. Traditional cerebrospinal fluid (CSF) biomarker methods such as positron emission tomography (PET) or lumbar puncture are often expensive, invasive, and not commonly accessible. Furthermore, this test incorporates the ultra-sensitive SimoaÒ technology from Quanterix with J&J Innovative Medicine’s thoroughly examined p-Tau 217 antibodies, promising exceptional accuracy, and a simplified process.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What Is the Regional Outlook for the Alzheimer’s Disease Diagnostic Market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093

This Report Delivers Insight On:

1. How big is the alzheimer’s disease diagnostic market, and how is it changing globally?

2. Who are the major companies in the alzheimer’s disease diagnostic market, and how are they performing?

3. What are the key opportunities and risks in the alzheimer’s disease diagnostic market right now?

4. Which products or customer segments are growing the most in the alzheimer’s disease diagnostic market?

5. What factors are helping or slowing down the growth of the alzheimer’s disease diagnostic market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model